Medtronic paces ahead
This article was originally published in The Gray Sheet
Executive Summary
Firm's Adapta, Versa and Sensia pacemakers offer "managed ventricular pacing" and "atrial capture management" to provide stimulation only as needed, the company said upon announcing the launch of the products. The technology has been shown to eliminate 99% of unnecessary pacing, reducing the risk of developing co-morbidities such as heart failure and atrial fibrillation, Medtronic says. The firm has been looking forward to this launch as a means of reasserting its hold on a vulnerable cardiac rhythm management market (1"The Gray Sheet" Feb. 27, 2006, p. 14)...
You may also be interested in...
Medtronic Readies New CRM Products To Protect Share Taken From Guidant
Medtronic is prepping three pacemakers for launch by May to compete against new products from competitor St. Jude and buttress against Guidant's potential comeback
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.